GSK expands AI drug discovery push with $110 million relation deal
FierceBiotech - 30-Jul-2026The aim is to make better choices early, before spending years developing a new medicine
The Live Forever Club is evolving. Subscribe to the newsletter to be the first to hear about this important change.
Senior editor of FierceBiotech
Business, science and healthcare journalist who has worked as an editor for Pharmafocus (UK), as a group editor for Pharmaceutical Marketing Europe, as well as a features and news writer for the BMJ and the Pharmaceutical Journal.
He has an especial interest in market access, drug pricing and the ethics of the life sciences industry and has been heavily involved in ensuring that the need for greater clinical study transparency remains on the agenda for the industry.
Visit website: https://www.fiercebiotech.com/author/ben-adams
See also
Web resource providing the latest biotech news, articles, and resources related to biotech company news
Details last updated 17-Jul-2020
The aim is to make better choices early, before spending years developing a new medicine
Musk says automated surgery and new implant design could speed BCI rollout for paralysis patients
AI-powered therapy offers new hope for ALS as early trials approach
Their lead treatment, EA-2353, shows promising safety results for retinitis pigmentosa
Supports ageing research and advancing early-stage projects to phase 2 trials over the next decade
rGDF11 in clinic targets multiple age related disease therapies
Novel autophagy-based approaches target muscular dystrophy and other challenging diseases
Biological clocks are a moving target so they'll need other researchers to corroborate their analysis